Liu N, Xu H, Solar Q, Yu X, Chen W, Wei H, Jiang J, Xu Y, Lu W. The position of oxidative stress in hyperuricemia and Xanthine Oxidoreductase (XOR) inhibitors. Oxid Med Cell Longev. 2021;2021:1470380.
Wang Z, Li Y, Liao W, Huang J, Liu Y, Li Z, Tang J. Intestine microbiota transforming: a promising therapeutic technique to confront hyperuricemia and gout. Entrance Cell Infect Microbiol. 2022;12:935723.
Dehlin M, Jacobsson L, Roddy E. International epidemiology of gout: prevalence, incidence, remedy patterns and threat components. Nat Rev Rheumatol. 2020;16(7):380–90.
Ejaz AA, Nakagawa T, Kanbay M, Kuwabara M, Kumar A, Garcia Arroyo FE, Roncal-Jimenez C, Sasai F, Kang DH, Jensen T, et al. Hyperuricemia in kidney illness: a serious threat issue for cardiovascular occasions, vascular calcification, and renal harm. Semin Nephrol. 2020;40(6):574–85.
Zhou X, Zhang B, Zhao X, Lin Y, Wang J, Wang X, Hu N, Wang S. Chlorogenic acid supplementation ameliorates hyperuricemia, relieves renal irritation, and modulates intestinal homeostasis. Meals Funct. 2021;12(12):5637–49.
Gherghina ME, Peride I, Tiglis M, Neagu TP, Niculae A, Checherita IA. Uric acid and oxidative stress-relationship with cardiovascular, metabolic, and renal impairment. Int J Mol Sci. 2022;23(6):3188.
Pan Z, Yang Ok, Wang H, Xiao Y, Zhang M, Yu X, Xu T, Bai T, Zhu H. MFAP4 deficiency alleviates renal fibrosis by inhibition of NF-κB and TGF-β/Smad signaling pathways. FASEB J. 2020;34(11):14250–63.
Xiao H, Solar X, Liu R, Chen Z, Lin Z, Yang Y, Zhang M, Liu P, Quan S, Huang H. Gentiopicroside prompts the bile acid receptor Gpbar1 (TGR5) to repress NF-kappaB pathway and ameliorate diabetic nephropathy. Pharmacol Res. 2020;151:104559.
Park JH, Jo YI, Lee JH. Renal results of uric acid: hyperuricemia and hypouricemia. Korean J Intern Med. 2020;35(6):1291–304.
Dalbeth N, Gosling AL, Gaffo A, Abhishek A. Gout. Lancet. 2021;397(10287):1843–55.
Danve A, Sehra ST, Neogi T. Function of food regimen in hyperuricemia and gout. Greatest Pract Res Clin Rheumatol. 2021;35(4):101723.
Chen L, Lan Z. Polydatin attenuates potassium oxonate-induced hyperuricemia and kidney irritation by inhibiting NF-κB/NLRP3 inflammasome activation through the AMPK/SIRT1 pathway. Meals Funct. 2017;8(5):1785–92.
Liu ZQ, Solar X, Liu ZB, Zhang T, Zhang LL, Wu CJ. Phytochemicals in conventional Chinese language medication can deal with gout by regulating intestinal flora by inactivating NLRP3 and inhibiting XOD exercise. J Pharm Pharmacol. 2022;74(7):919–29.
Foresto-Neto O, Ávila VF, Arias SCA, Zambom FFF, Rempel LCT, Faustino VD, Machado FG, Malheiros D, Abensur H, Camara NOS, et al. NLRP3 inflammasome inhibition ameliorates tubulointerstitial harm within the remnant kidney mannequin. Lab Make investments. 2018;98(6):773–82.
Haryono A, Nugrahaningsih DAA, Sari DCR, Romi MM, Arfian N. Discount of serum uric acid related to attenuation of renal harm, irritation and macrophages M1/M2 ratio in hyperuricemic mice mannequin. Kobe J Med Sci. 2018;64(3):E107–14.
Zhao Y, Xu L, Tian D, Xia P, Zheng H, Wang L, Chen L. Results of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid stage: a meta-analysis of randomized managed trials. Diabetes Obes Metab. 2018;20(2):458–62.
Suijk DLS, van Baar MJB, van Bommel EJM, Iqbal Z, Krebber MM, Vallon V, Touw D, Hoorn EJ, Nieuwdorp M, Kramer MMH, et al. SGLT2 inhibition and uric acid excretion in sufferers with sort 2 diabetes and regular kidney perform. Clin J Am Soc Nephrol. 2022;17(5):663–71.
Li A, Liang L, Liang P, Hu Y, Xu C, Hu X, Shen Y, Hu D, Li Z, Kamel IR. Evaluation of renal fibrosis in a rat mannequin of unilateral ureteral obstruction with diffusion kurtosis imaging: comparability with α-SMA expression and (18)F-FDG PET. Magn Reson Imaging. 2020;66:176–84.
Liu Y, Zhang GM, Peng X, Wen Y, Ye W, Zheng Ok, Li X, Solar H, Chen L. Diffusional kurtosis imaging in assessing renal perform and pathology of IgA nephropathy: a preliminary scientific examine. Clin Radiol. 2018;73(9):818–26.
Bonani M, Seeger H, Weber N, Lorenzen JM, Wüthrich RP, Kistler AD. Security of kidney biopsy when carried out as an outpatient process. Kidney Blood Press Res. 2021;46(3):310–22.
Zhou H, Zhang J, Zhang XM, Chen T, Hu J, Jing Z, Jian S. Noninvasive analysis of early diabetic nephropathy utilizing diffusion kurtosis imaging: an experimental examine. Eur Radiol. 2021;31(4):2281–8.
Mao W, Ding Y, Ding X, Fu C, Zeng M, Zhou J. Diffusion kurtosis imaging for the evaluation of renal fibrosis of continual kidney illness: a preliminary examine. Magn Reson Imaging. 2021;80:113–20.
Johnson RJ, Bakris GL, Borghi C, Chonchol MB, Feldman D, Lanaspa MA, Merriman TR, Moe OW, Mount DB, Sanchez Lozada LG, et al. Hyperuricemia, acute and continual kidney illness, hypertension, and heart problems: report of a scientific workshop organized by the Nationwide Kidney Basis. Am J Kidney Dis. 2018;71(6):851–65.
Jensen JH, Helpern JA, Ramani A, Lu H, Kaczynski Ok. Diffusional kurtosis imaging: the quantification of non-gaussian water diffusion via magnetic resonance imaging. Magn Reson Med. 2005;53(6):1432–40.
Hu G, Liang W, Wu M, Lai C, Mei Y, Li Y, Xu J, Luo L, Quan X. Comparability of T1 Mapping and T1rho values with standard diffusion-weighted imaging to evaluate fibrosis in a rat mannequin of unilateral ureteral obstruction. Acad Radiol. 2019;26(1):22–9.
Wang B, Wang Y, Li L, Guo J, Wu PY, Zhang H, Zhang H. Diffusion kurtosis imaging and arterial spin labeling for the noninvasive analysis of persistent post-contrast acute kidney harm. Magn Reson Imaging. 2022;87:47–55.
Pentang G, Lanzman RS, Heusch P, Müller-Lutz A, Blondin D, Antoch G, Wittsack HJ. Diffusion kurtosis imaging of the human kidney: a feasibility examine. Magn Reson Imaging. 2014;32(5):413–20.
Rosenkrantz AB, Padhani AR, Chenevert TL, Koh DM, De Keyzer F, Taouli B, Le Bihan D. Physique diffusion kurtosis imaging: fundamental rules, functions, and concerns for scientific apply. J Magn Reson Imaging. 2015;42(5):1190–202.
Filli L, Wurnig M, Nanz D, Luechinger R, Kenkel D, Boss A. Complete-body diffusion kurtosis imaging: preliminary expertise on non-Gaussian diffusion in numerous organs. Make investments Radiol. 2014;49(12):773–8.
Li A, Yuan G, Hu Y, Shen Y, Hu X, Hu D, Li Z. Renal purposeful and interstitial fibrotic evaluation with non-Gaussian diffusion kurtosis imaging. Insights Imaging. 2022;13(1):70.
La Grotta R, de Candia P, Olivieri F, Matacchione G, Giuliani A, Rippo MR, Tagliabue E, Mancino M, Rispoli F, Ferroni S, et al. Anti-inflammatory impact of SGLT-2 inhibitors through uric acid and insulin. Cell Mol Life Sci. 2022;79(5):273.
Abdollahi E, Keyhanfar F, Delbandi AA, Falak R, Hajimiresmaiel SJ, Shafiei M. Dapagliflozin exerts anti-inflammatory results through inhibition of LPS-induced TLR-4 overexpression and NF-κB activation in human endothelial cells and differentiated macrophages. Eur J Pharmacol. 2022;918:174715.
Bailey CJ, Day C, Bellary S. Renal safety with SGLT2 inhibitors: results in acute and continual kidney illness. Curr DiabRep. 2022;22(1):39–52.
He L, Fan Y, Xiao W, Chen T, Wen J, Dong Y, Wang Y, Li S, Xue R, Zheng L, et al. Febuxostat attenuates ER stress mediated kidney harm in a rat mannequin of hyperuricemic nephropathy. Oncotarget. 2017;8(67):111295–308.
Wang Y, Kong W, Wang L, Zhang T, Huang B, Meng J, Yang B, Xie Z, Zhou H. A number of-purpose connectivity map evaluation reveals the advantages of Esculetin to hyperuricemia and renal fibrosis. Int J Mol Sci. 2020;21(20):7695.
Kjølby BF, Khan AR, Chuhutin A, Pedersen L, Jensen JB, Jakobsen S, Zeidler D, Sangill R, Nyengaard JR, Jespersen SN, et al. Quick diffusion kurtosis imaging of fibrotic mouse kidneys. NMR Biomed. 2016;29(12):1709–19.
